Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teprotumumab - Horizon Therapeutics

Next Previous
Drug Profile

Teprotumumab - Horizon Therapeutics

Alternative Names: HZN 001; Insulin-like-growth-factor-1-receptor-antagonist-antibody-River-Vision-Development; R 1507; RG 1507; RO-4858696; RV 001-River-Vision; Tepezza; teprotumumab-trbw

Latest Information Update: 21 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Roche
  • Developer Halozyme Therapeutics; Horizon Therapeutics plc; Roche
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IGF type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graves ophthalmopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Graves ophthalmopathy
  • Discontinued Advanced breast cancer; Diabetic macular oedema; Diffuse scleroderma; Hodgkin's disease; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Sarcoma; Solid tumours

Most Recent Events

  • 07 May 2025 Registered for Graves ophthalmopathy in United Kingdom (IV)
  • 25 Apr 2025 European Medicines Agency (EMA) recommends approval of teprotumumab for Graves ophthalmopathy in European Union (EU)
  • 04 Feb 2025 European Medicines Agency anticipates approval for Teprotumumab for the treatment of Graves opthalmopathy in H2 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top